Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - IL
$ 1.92
-8.13 %
$ 3.28 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart PRFX
FINANCIALS
Balance Sheet
PainReform Ltd.
| Current Assets | 9.8 M |
| Cash & Short-Term Investments | 8.03 M |
| Receivables | 45 K |
| Other Current Assets | 1.73 M |
| Non-Current Assets | 131 K |
| Long-Term Investments | 0 |
| PP&E | 131 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 2.41 M |
| Accounts Payable | 221 K |
| Short-Term Debt | 56 K |
| Other Current Liabilities | 2.13 M |
| Non-Current Liabilities | 281 K |
| Long-Term Debt | 30 K |
| Other Non-Current Liabilities | 251 K |
EFFICIENCY
Earnings Waterfall
PainReform Ltd.
| Revenue | 0 |
| Cost Of Revenue | 15 K |
| Gross Profit | -15 K |
| Operating Expenses | 9.58 M |
| Operating Income | -9.58 M |
| Other Expenses | -240 K |
| Net Income | -9.34 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
PainReform Ltd.
| Net Income | -9.34 M |
| Depreciation & Amortization | 15 K |
| Capital Expenditures | -9 K |
| Stock-Based Compensation | 804 K |
| Change in Working Capital | 1.63 M |
| Others | 1.83 M |
| Free Cash Flow | -6.69 M |
Wall Street Analysts Price Targets
PainReform Ltd.
PRFX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PRFX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
PainReform Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PainReform Provides Year-End Business Update
TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of the DeepSolar activities, today provided a business update for the year ended December 31, 2024.
globenewswire.com
- 1 week ago
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation
globenewswire.com
- 1 month ago
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has executed a definitive agreement with BladeRanger Ltd, a public company registered under the laws of the State of Israel, whose shares are listed for trading on Tel Aviv Stock Exchange under the ticker “BLRN” (the “BLRN”) to acquire 100% of the business activity of DeepSolar, an AI-driven solar analytics platform owned by BLRN (the “Agreement”).
globenewswire.com
- 2 months ago
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
globenewswire.com
- 3 months ago
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
globenewswire.com
- 4 months ago
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer satisfied the minimum $2.5 million stockholders' equity requirement for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”) or, alternatively, the requirement that the Company either maintain a market value of listed securities of at least $35 million or generate net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years.
globenewswire.com
- 5 months ago
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management
globenewswire.com
- 7 months ago
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the Company originally issued in December 2023 and April 2024, having an exercise price of $4.80 per share, at a reduced exercise price of $1.60 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (File No. 333-276485) and Form F-1 (File No. 333-277594). The offering is expected to close on or about September 11, 2024, subject to satisfaction of customary closing conditions.
globenewswire.com
- 7 months ago
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company's proprietary post-surgical pain formulation.
globenewswire.com
- 8 months ago
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold.
globenewswire.com
- 8 months ago
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
New process expected to significantly bolster future commercialization efforts New process expected to significantly bolster future commercialization efforts
globenewswire.com
- 8 months ago
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
globenewswire.com
- 10 months ago
8. Profile
Summary
PainReform Ltd. PRFX
COUNTRY
IL
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 3.28 M
Dividend Yield
0.00%
Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Contact
65 Yigal Alon Street, Tel Aviv, 6745442
https://www.painreform.com
IPO
Date
Sept. 1, 2020
Employees
7
Officers
Ms. Rita Keynan
Vice President of Pharmaceutical Operations
Dr. Ehud Geller Ph.D.
Interim Chief Executive Officer & Executive Chairman
Dr. Sigal Aviel
Chief Operating Officer
Prof. Eli Hazum Ph.D.
Chief Technology Officer & Director
Mr. Eyal Broder
Interim Chief Financial Officer
Dr. Stephen A. Cooper D.M.D Ph.D.
Executive Vice President of Development